Antiangiogenic Factors in Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

The Role of Endogenous Antiangiogenic Factors in Gastric Cancer Progression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00735566
• Other study ID #: NCCCTS 04-105
• Status: Completed
• Phase: N/A
• First received: August 13, 2008
• Last updated: October 16, 2012
• Start date: April 2006
• Est. completion date: January 2012

Study information

• Verified date: October 2012
• Source: National Cancer Center, Korea
• Contact: n/a
• Is FDA regulated: No
• Health authority: South Korea: Korea Food and Drug Administration (KFDA)
• Study type: Observational

Clinical Trial Summary

Endogenous antiangiogenic factors are related with gastric cancer progression.

Description:

Gastric cancers have been known to secrete the proangiogenic cytokine VEGF in vitro and in vivo. Tumor VEGF expression is correlated with the severity of disease in patients with gastric cancer and some authors have suggested using circulating VEGF as a prognostic factor or tumor marker.In addition to producing proangiogenic cytokines, recent data demonstrate that tumors can produce antiangiogenic cytokine as well. It has been suggested that, in humans, the generation of antiangiogenic compounds in the presence of a primary tumor suppresses the growth of distant metastases. This phenomenon has been demonstrated in mice and in patients with clear cell renal cancer, breast cancer, and colorectal cancer. However, the presence of endogenous antiangiogenic cytokines in patients with gastric cancer has not been reported.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 240
• Est. completion date: January 2012
• Est. primary completion date: July 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• Histologic diagnosis of gastric adenocarcinoma

• No other forms of cancer therapy, such as chemotherapy or radiotherapy for at least 3 weeks before the enrollment in study

• Performance status of 0, 1, 2 on the ECOG criteria

• ASA class I, II

• Patient compliance that allow adequate follow up

• Informed consent from patient or patient's relative.

Exclusion Criteria:

• Second primary malignancy

• EMR (Endoscopic mucosal resection) indication

• Laparoscopic gastrectomy

• Radiologic or clinical evidence of metastasis

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Locations

Country	Name	City	State
Korea, Republic of	National Cancer Center	Goyang-si	Geonggi-do

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Center, Korea

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relationship between antiangiogenic factor and tumor, node, metastasis		One year	No
Secondary	Overall survival, treatment failure		5 years	No